InterBio Completes Pre-A Financing Round with Haoyue Capital as Exclusive Financial Advisor

VCBeat has learned that recently, China's surface plasmon resonance (SPR Technology Platform Leader Yingbai Bio Announces Completion of Pre-A Financing Round, Invested by Jintan Capital, with Haoyue Capital Serving as the Exclusive Financial Advisor. This round of financing will support Yingbai Bio’s commercial installation, mass production, market promotion and sales, laboratory construction to expand production capacity, and continuous R&D investment in new products.

Yingbo Biotech, established in 2013, is dedicated to the research and development, manufacturing, application promotion, and technical services of surface plasmon resonance (SPR) technology and other life science analytical instruments. It is a pioneer of SPR technology platforms in China. Recognized as a National High-Tech Enterprise, the company has been granted more than 20 patents, with an additional five patent applications pending. The founding team has over ten years of deep expertise in the SPR field, demonstrating outstanding capabilities in R&D-to-production transfer, supplier development, and supply chain management. They have successfully developed China’s first commercially available SPR product with fully independent intellectual property rights, achieving 100% domestic production of core components. The expert support team comprises seasoned SPR application and marketing specialists as well as leading scientists from top-tier research institutions, providing robust and practical support for the company’s sustained growth.

Yingbo Bio has spent years developing and launching the MI-S200 series of molecular interaction analysis systems, the first commercially available SPR platform in China with 100% independent intellectual property rights that rivals international monopoly brands. This achievement has broken the dominance of imported brands, contributing to the resolution of critical technological bottlenecks in China, and has already secured multiple overseas orders. The company’s globally unique, pioneering online protein activity detector, Lark-10, is coupled with liquid chromatography to simultaneously achieve chromatographic separation and affinity detection of complex samples. Additionally, essential omics laboratory instruments successively introduced by the company, such as single-cell omics workstations, are playing significant roles in national-level laboratories including the National Center for Protein Sciences.

Intermolecular interactions are central to life processes, and the detection and analysis of these interactions provide critical support for fundamental research in life sciences, studies on disease etiology and pathopathology, drug research and development, and clinical testing. Surface plasmon resonance (SPR) technology, recognized as the “gold standard” for studying intermolecular interactions, has been included in the 2020 edition of the Pharmacopoeia of the People's Republic of China.

In recent years, the domestic substitution of high-end life science instruments has become an inevitable trend. The Inber team is committed to catching up with international giants and continuously providing customers with high-quality products and services. With the support of this round of financing, Inber Biology will accelerate the scaled mass production and market promotion of existing products, increase R&D investment in new products, expand its team, and continually speed up the expansion of its product portfolio.

Mr. Li Hongzeng, Founder of Yingbai BiotechThe company expressed its sincere gratitude to all investors for their trust and recognition of Yingbai Biology. The rapid advancement of global life sciences basic research and biopharmaceuticals has fueled the rise of life science instrumentation. With the inevitable trend of domestic substitution for high-end life science instruments, Yingbai Biology will focus on products and technologies related to “molecular interactions” and “omics,” continuously providing more valuable product and technological solutions to support the industrialization of life sciences, ultimately contributing to healthier lives!

Mr. Huang Huawei, Founding Partner of Jintan CapitalIt was stated that label-free molecular interaction detection systems, particularly Surface Plasmon Resonance (SPR) instruments, are indispensable core equipment for basic research in biopharmaceuticals and life sciences. Due to their involvement in multiple disciplines—including optics, automation, biology, and sensing control—these instruments feature complex structures. Domestic technologies have long failed to achieve breakthroughs, leaving the Chinese market monopolized by imported brands. Under the leadership of its founder, Mr. Li Hongzeng, Yingbai Bio has maintained continuous R&D investment over the years, successfully developing and mass-producing the MI-S200 series, thereby breaking this status quo. Jintan Capital will remain firmly committed to supporting Yingbai Bio’s development and looks forward to the company’s future development of more high-end biological instruments, contributing to the growth of China’s biopharmaceutical industry.

Mr. Ding Yameng, Founding Managing Partner and Chief Operating Officer of Hywin Capitalstated, “We are honored to serve as the exclusive financial advisor for Inber Bio’s current round of financing and to assist the company in completing this transaction. Upstream life sciences equipment, serving as the foundational infrastructure for life sciences research, is characterized by high technological barriers and a low rate of domestic production, thereby facing significant risks of supply chain bottlenecks. Inber Bio has been deeply engaged in the field of high-end life science instruments for many years, having taken the lead in breaking the import monopoly in the Surface Plasmon Resonance (SPR) sector and achieving overseas sales, making it a scarce and valuable asset within China. We remain bullish on Inber Bio’s development and look forward to the company accelerating import substitution under favorable policies and capital support, thereby delivering more high-quality, high-value innovative products and solutions to its customers.”

Jintan Capital is a boutique investment firm specializing in the pharmaceutical and healthcare sectors. Guided by its core philosophy of “creating value and pursuing excellence,” Jintan Capital implements the VIC-P innovation-driven development model in the biopharmaceutical industry. Its keen market insight, visionary foresight, forward-looking international perspective, and global resource coordination and integration—combined with extensive and mature operational expertise in pharmaceuticals, healthcare, and the broader health industry—have established Jintan Capital’s leading investment prowess. Multiple portfolio companies invested by Jintan Capital have filed for listings on the ChiNext Board or the STAR Market, while others have achieved exit through mergers and acquisitions, delivering substantial returns to investors.

Haoyue Capital, established in January 2014, is a leading industry-focused investment bank in China specializing in the healthcare sector. Headquartered in Shanghai, the firm maintains regional offices in Beijing and Shenzhen. Haoyue Capital is committed to leveraging capital and research-driven insights to help outstanding Chinese healthcare companies successfully access the capital markets, thereby creating value-added benefits for its clients. The partnership team at Haoyue Capital comprises seasoned investment bankers with extensive experience in China’s healthcare sector, supported by a professional team of over 70 members. Haoyue Capital closely monitors dynamics and trends in the healthcare investment market, with its research and transaction coverage spanning multiple sub-sectors, including innovative pharmaceuticals, innovative medical devices, IVD and life sciences, health services, and smart healthcare. In 2021, Haoyue Capital completed more than 50 complex transactions involving private equity financing, mergers and acquisitions, and spin-offs of listed companies, with a total transaction value amounting to tens of billions of RMB, maintaining a comprehensive leadership position across various healthcare sub-sectors.